Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Mar 17;172(6):369-380.
doi: 10.7326/M19-3369. Epub 2020 Feb 18.

Adverse Effects of Low-Dose Methotrexate: A Randomized Trial

Daniel H Solomon  1 , Robert J Glynn  1 , Elizabeth W Karlson  1 , Fengxin Lu  1 , Cassandra Corrigan  1 , Josh Colls  1 , Chang Xu  1 , Jean MacFadyen  1 , Medha Barbhaiya  2 , Nancy Berliner  1 , Paul F Dellaripa  1 , Brendan M Everett  1 , Aruna D Pradhan  1 , Sarah P Hammond  1 , Meredith Murray  1 , Deepak A Rao  1 , Susan Y Ritter  1 , Anna Rutherford  1 , Jeffrey A Sparks  1 , Jackie Stratton  1 , Dong H Suh  1 , Sara K Tedeschi  1 , Kathleen M M Vanni  1 , Nina P Paynter  1 , Paul M Ridker  1
Affiliations
Randomized Controlled Trial

Adverse Effects of Low-Dose Methotrexate: A Randomized Trial

Daniel H Solomon et al. Ann Intern Med. .

Abstract

Background: Low-dose methotrexate (LD-MTX) is the most commonly used drug for systemic rheumatic diseases worldwide and is the recommended first-line agent for rheumatoid arthritis. Despite extensive clinical use for more than 30 years, few data on adverse event (AE) rates derive from randomized, placebo-controlled trials, where both causality and magnitude of risk can be inferred.

Objective: To investigate AE rates, risk, and risk differences comparing LD-MTX versus placebo.

Design: Prespecified secondary analyses of a double-blind, placebo-controlled, randomized trial. (ClinicalTrials.gov: NCT01594333).

Setting: North America.

Participants: Adults with known cardiovascular disease and diabetes or metabolic syndrome.

Intervention: Random allocation to LD-MTX (≤20 mg/wk) or placebo. All participants received folic acid, 1 mg/d, 6 days per week.

Measurements: Risks for specific AEs of interest, as well as for all AEs, were compared across treatment groups after blinded adjudication.

Results: After an active run-in period, 6158 patients were enrolled and 4786 randomly assigned to a group; median follow-up was 23 months and median dosage 15 mg/wk. Among the randomly assigned participants, 81.2% were male, median age was 65.7 years, and median body mass index was 31.5 kg/m2. Of 2391 participants assigned to LD-MTX, 2080 (87.0%) had an AE of interest, compared with 1951 of 2395 (81.5%) assigned to placebo (hazard ratio [HR], 1.17 [95% CI, 1.10 to 1.25]). The relative hazards of gastrointestinal (HR, 1.91 [CI, 1.75 to 2.10]), pulmonary (HR, 1.52 [CI, 1.16 to 1.98]), infectious (HR, 1.15 [CI, 1.01 to 1.30]), and hematologic (HR, 1.15 [CI, 1.07 to 1.23]) AEs were elevated for LD-MTX versus placebo. With the exception of increased risk for skin cancer (HR, 2.05 [CI, 1.28 to 3.28]), the treatment groups did not differ in risk for other cancer or mucocutaneous, neuropsychiatric, or musculoskeletal AEs. Renal AEs were reduced in the LD-MTX group (HR, 0.85 [CI, 0.78 to 0.93]).

Limitation: The trial was done in patients without rheumatic disease who tolerated LD-MTX during an active run-in period.

Conclusion: Use of LD-MTX was associated with small to moderate elevations in risks for skin cancer and gastrointestinal, infectious, pulmonary, and hematologic AEs, whereas renal AEs were decreased.

Primary funding source: National Institutes of Health.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Cumulative incidence plots with 95% confidence intervals for the modified intention to treat analyses, censoring 180 days after the last dosage of study drug. Log-rank test was used to estimate the p-value. Abbreviations: LD-MTX, low dose methotrexate; PBO, placebo. Panel A: All adverse events of interest with laboratory abnormalities included. Panel B: Any hematologic adverse events with laboratory abnormalities included. Panel C: All cancer adverse events. Panel D: All liver adverse events with laboratory abnormalities included. Panel E: All gastrointestinal adverse events, excluding liver and liver test abnormalities. Panel F: All infectious adverse events. Panel G: All pulmonary adverse events.
Figure 1:
Figure 1:
Cumulative incidence plots with 95% confidence intervals for the modified intention to treat analyses, censoring 180 days after the last dosage of study drug. Log-rank test was used to estimate the p-value. Abbreviations: LD-MTX, low dose methotrexate; PBO, placebo. Panel A: All adverse events of interest with laboratory abnormalities included. Panel B: Any hematologic adverse events with laboratory abnormalities included. Panel C: All cancer adverse events. Panel D: All liver adverse events with laboratory abnormalities included. Panel E: All gastrointestinal adverse events, excluding liver and liver test abnormalities. Panel F: All infectious adverse events. Panel G: All pulmonary adverse events.
Figure 1:
Figure 1:
Cumulative incidence plots with 95% confidence intervals for the modified intention to treat analyses, censoring 180 days after the last dosage of study drug. Log-rank test was used to estimate the p-value. Abbreviations: LD-MTX, low dose methotrexate; PBO, placebo. Panel A: All adverse events of interest with laboratory abnormalities included. Panel B: Any hematologic adverse events with laboratory abnormalities included. Panel C: All cancer adverse events. Panel D: All liver adverse events with laboratory abnormalities included. Panel E: All gastrointestinal adverse events, excluding liver and liver test abnormalities. Panel F: All infectious adverse events. Panel G: All pulmonary adverse events.
Figure 1:
Figure 1:
Cumulative incidence plots with 95% confidence intervals for the modified intention to treat analyses, censoring 180 days after the last dosage of study drug. Log-rank test was used to estimate the p-value. Abbreviations: LD-MTX, low dose methotrexate; PBO, placebo. Panel A: All adverse events of interest with laboratory abnormalities included. Panel B: Any hematologic adverse events with laboratory abnormalities included. Panel C: All cancer adverse events. Panel D: All liver adverse events with laboratory abnormalities included. Panel E: All gastrointestinal adverse events, excluding liver and liver test abnormalities. Panel F: All infectious adverse events. Panel G: All pulmonary adverse events.
Figure 1:
Figure 1:
Cumulative incidence plots with 95% confidence intervals for the modified intention to treat analyses, censoring 180 days after the last dosage of study drug. Log-rank test was used to estimate the p-value. Abbreviations: LD-MTX, low dose methotrexate; PBO, placebo. Panel A: All adverse events of interest with laboratory abnormalities included. Panel B: Any hematologic adverse events with laboratory abnormalities included. Panel C: All cancer adverse events. Panel D: All liver adverse events with laboratory abnormalities included. Panel E: All gastrointestinal adverse events, excluding liver and liver test abnormalities. Panel F: All infectious adverse events. Panel G: All pulmonary adverse events.
Figure 1:
Figure 1:
Cumulative incidence plots with 95% confidence intervals for the modified intention to treat analyses, censoring 180 days after the last dosage of study drug. Log-rank test was used to estimate the p-value. Abbreviations: LD-MTX, low dose methotrexate; PBO, placebo. Panel A: All adverse events of interest with laboratory abnormalities included. Panel B: Any hematologic adverse events with laboratory abnormalities included. Panel C: All cancer adverse events. Panel D: All liver adverse events with laboratory abnormalities included. Panel E: All gastrointestinal adverse events, excluding liver and liver test abnormalities. Panel F: All infectious adverse events. Panel G: All pulmonary adverse events.
Figure 1:
Figure 1:
Cumulative incidence plots with 95% confidence intervals for the modified intention to treat analyses, censoring 180 days after the last dosage of study drug. Log-rank test was used to estimate the p-value. Abbreviations: LD-MTX, low dose methotrexate; PBO, placebo. Panel A: All adverse events of interest with laboratory abnormalities included. Panel B: Any hematologic adverse events with laboratory abnormalities included. Panel C: All cancer adverse events. Panel D: All liver adverse events with laboratory abnormalities included. Panel E: All gastrointestinal adverse events, excluding liver and liver test abnormalities. Panel F: All infectious adverse events. Panel G: All pulmonary adverse events.
See this image and copyright information in PMC

Comment in

References

    1. Sparks JA, Barbhaiya M, Karlson EW, Ritter SY, Raychaudhuri S, Corrigan CC, et al. Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. Semin Arthritis Rheum. 2017;47(1):133–42. - PMC - PubMed
    1. Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F. Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature. Int J Rheumatol. 2011;2011:845496. - PMC - PubMed
    1. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum. 2006;55(6):864–72. - PubMed
    1. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312(13):818–22. - PubMed
    1. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol. 1998;25(2):238–42. - PubMed

Publication types

Associated data